Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Thermal Magnetic Resonance-based Ablation Cancer Therapy

Project description

Non-invasive ablation therapy for cancer

Ablation therapy procedures apply heat or cold to target and destroy tumours. However, current methods utilise invasive probes, which restrict treatment to easily accessible tumours and pose a risk of harming surrounding healthy tissue. The ERC-funded MR-ACT project intends to address these limitations by leveraging MRI technology for precise targeting, real-time temperature monitoring and controlled therapy delivery. The MR-ACT approach aims to achieve ablative temperatures above 60 °C with millimetre-level accuracy, all without the need for surgical intervention. Such advancements have the potential to broaden the range of treatable tumour sites. Overall, this new method is expected to enhance oncological interventions and improve clinical outcomes for cancer patients.

Objective

The MR-ACT project will develop Thermal Magnetic Resonance-based Ablation Cancer Therapy, a groundbreaking non-invasive approach that eliminates the need for invasive needle electrodes or fibre optic Laser probes in cancer ablation procedures. Building upon innovations from our ERC Advanced Grant ThermalMR, we will advance our proprietary high-density radiofrequency (RF) applicator technology to achieve ablative temperatures (>60°C) for tumour tissue destruction while maintaining millimetre-precision targeting and comprehensive MRI-based monitoring. Current radiofrequency or laser ablation approaches require invasive needle or fibre optic probe insertion, causing collateral damage, risking tumour seeding, limiting treatment to accessible anatomical locations, and increasing healthcare costs through hospitalization requirements. MR-ACT addresses these limitations by integrating diagnostic imaging, thermal treatment, temperature measurement and therapy monitoring in a single device without physical penetration of the body. This 18-month project will systematically refine the RF applicator technology for ablation temperatures, validate performance in anthropomorphic phantoms mimicking clinical scenarios, develop comprehensive IP protection and regulatory strategies, analyse market opportunities, and create a detailed commercialization roadmap. The technology enables treatment of previously inaccessible tumours, reduces procedural complexity, potentially enables outpatient treatment workflows, and improves patient experience while reducing healthcare costs. MR-ACT represents a high-risk, high-gain opportunity to fundamentally transform cancer treatment approaches. Our innovative non-invasive ablation technology could expand treatment options for patients with limited alternatives, establish a new paradigm in interventional oncology, and create significant commercial opportunities through technology licensing or spin-off company formation.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Net EU contribution
€ 150 000,00
Address
ROBERT ROSSLE STRASSE 10
13125 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)